Synthetic medicinal compounds for the treatment of hepatitis C | Abstract

Der Pharma Chemica
Journal for Medicinal Chemistry, Pharmaceutical Chemistry, Pharmaceutical Sciences and Computational Chemistry

ISSN: 0975-413X
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission Systemof respective journal.


Synthetic medicinal compounds for the treatment of hepatitis C

Author(s): Mohd. Imran, Abida, Said A. El-Feky, Sibghatullah Sangi

Hepatitis C has become a major clinical and public health problem worldwide. Accordingly, pharmaceutical research companies are making efforts to develop new synthetic medicinal compounds along with biologics, drug combinations and new dosage forms. The approval of two new synthetic medicinal compounds in late 2013 namely sofosbuvir and simeprevir by the U.S. Food and Drug Administration (U.S. FDA) for the treatment of hepatitis C is the result of the efforts made by these pharmaceutical research companies. The U.S. FDA approved synthetic medicinal compounds have opened the door for the oral regimens as the future standard of treatment for hepatitis C. This review article provides preliminary information about recently approved synthetic medicinal compounds as well as some important synthetic medicinal compounds in the pipeline for the treatment of hepatitis C.


Select your language of interest to view the total content in your interested language

30+ Million Readerbase
SCImago Journal & Country Rank
Recommended Conferences
Google Scholar citation report
Citations : 23677

Der Pharma Chemica received 23677 citations as per Google Scholar report

Der Pharma Chemica peer review process verified at publons
Der Pharma Chemica- Journals on pharmaceutical chemistry